BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LAB21 Limited Announces Appointment of Industry Expert Fraser Logue


2/21/2012 9:24:33 AM

Cambridge, UK – 20 February 2012 - Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the appointment of Fraser Logue as Group Director of Quality, Regulatory Affairs & Operations Excellence based in the UK.

Dr Logue served two decades in divisions of Abbott Laboratories, most recently as Division Vice President World Wide Manufacturing for Abbott Diabetes Care, moving from Division Vice President European Operations. He previously served as Operations Director for Abbott Diagnostics Division Ireland, Director of Quality & Regulatory and Marketing Manager for Abbott Diagnostics Division in Germany.

Graham Mullis, CEO of Lab21, said: “I am delighted to have someone of Fraser’s experience join Lab21, especially at a time when we expect to see significant organic growth during the next few years. His senior level international management experience and operations capabilities will ensure Lab21 will meet the demands of increasing sales, entering new markets including the US and the launch of new products.”

Dr Logue said: “Lab21 has achieved remarkable progress within the past 4 years, growing five times in size. I am looking forward to working with and contributing to the future success of Lab21.”

For further information:

Lab21

Graham Mullis, CEO

t: +44 (0)1223 395450

e: graham.mullis@lab21.com

For media and investor enquiries:

College Hill

Nicole Yost/Dimithri Wignarajah

t: +44 (0)20 7457 2020

e: lab21@collegehill.com

About Lab21

Lab21 is a global leader in personalized healthcare. It provides diagnostic products and services and supports blood bank screening, medical diagnostics and drug discovery. Lab21 customers include international healthcare providers, pharmaceutical and diagnostic companies. The Products division of Lab21 manufactures immunodiagnostic kits and reagents that are distributed internationally and is focused on infectious diseases for the blood-banking and clinical markets. Our clinical services operations have a growing test portfolio providing companion diagnostics and high technology molecular assays. Lab21's corporate offices are based in Cambridge, UK and Greenville, South Carolina, with a GMP manufacturing site in Cambridge and other manufacturing facilities in Newmarket, Camberley, Manchester and Bridport. Website: www.lab21.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES